1. Home
  2. PBM vs SNGX Comparison

PBM vs SNGX Comparison

Compare PBM & SNGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • PBM
  • SNGX
  • Stock Information
  • Founded
  • PBM 1994
  • SNGX 1987
  • Country
  • PBM Canada
  • SNGX United States
  • Employees
  • PBM N/A
  • SNGX N/A
  • Industry
  • PBM
  • SNGX Biotechnology: Pharmaceutical Preparations
  • Sector
  • PBM
  • SNGX Health Care
  • Exchange
  • PBM NYSE
  • SNGX Nasdaq
  • Market Cap
  • PBM 5.3M
  • SNGX 7.4M
  • IPO Year
  • PBM N/A
  • SNGX 1987
  • Fundamental
  • Price
  • PBM $1.40
  • SNGX $2.39
  • Analyst Decision
  • PBM
  • SNGX
  • Analyst Count
  • PBM 0
  • SNGX 0
  • Target Price
  • PBM N/A
  • SNGX N/A
  • AVG Volume (30 Days)
  • PBM 417.9K
  • SNGX 44.9K
  • Earning Date
  • PBM 02-02-2025
  • SNGX 03-14-2025
  • Dividend Yield
  • PBM N/A
  • SNGX N/A
  • EPS Growth
  • PBM N/A
  • SNGX N/A
  • EPS
  • PBM N/A
  • SNGX N/A
  • Revenue
  • PBM N/A
  • SNGX $364,183.00
  • Revenue This Year
  • PBM N/A
  • SNGX N/A
  • Revenue Next Year
  • PBM N/A
  • SNGX $76.64
  • P/E Ratio
  • PBM N/A
  • SNGX N/A
  • Revenue Growth
  • PBM N/A
  • SNGX N/A
  • 52 Week Low
  • PBM $1.15
  • SNGX $1.83
  • 52 Week High
  • PBM $323.25
  • SNGX $14.88
  • Technical
  • Relative Strength Index (RSI)
  • PBM 41.45
  • SNGX 43.83
  • Support Level
  • PBM $1.15
  • SNGX $2.25
  • Resistance Level
  • PBM $1.59
  • SNGX $2.60
  • Average True Range (ATR)
  • PBM 0.20
  • SNGX 0.15
  • MACD
  • PBM 0.03
  • SNGX 0.03
  • Stochastic Oscillator
  • PBM 27.53
  • SNGX 52.27

About PBM PSYENCE BIOMEDICAL LTD

Psyence Biomedical Ltd is a life science biotechnology company pioneering the use of natural psychedelics in mental health and wellbeing. It develops natural psilocybin products for the healing of psychological trauma and its mental health consequences in the context of palliative care. The company has commenced the clinical trial process to evaluate the safety and efficacy of its product candidates. It cultivates natural psilocybin mushrooms at its federally licensed facility in Southern Africa. This product is produced for export to its partners across the world to be processed into a standardized encapsulated product.

About SNGX Soligenix Inc.

Soligenix Inc is a late-stage biopharmaceutical company based in the United States. It focuses on developing and commercializing products to treat rare diseases where there is an unmet medical need. The company operates through two business segments namely Specialized BioTherapeutics and Public Health Solutions. It generates maximum revenue from Public Health Solutions with active development programs for RiVax, its ricin toxin vaccine candidate, SGX943, its therapeutic candidate for antibiotic resistant and emerging infectious disease, and its research programs to identify and develop novel vaccine candidates targeting viral infection including Ebola, Marburg and SARS-CoV-2 (the cause of COVID-19).

Share on Social Networks: